Selected article for: "acute cause respiratory syndrome and clinical research"
Author: Chan, Jasper Fuk-Woo; Lau, Susanna Kar-Pui; Woo, Patrick Chiu-Yat
Title: The emerging novel Middle East respiratory syndrome coronavirus: The “knowns” and “unknowns”
  • Cord-id: row2mn17
  • Document date: 2013_7_21
    • ID: row2mn17
    Snippet: A novel lineage C betacoronavirus, originally named human coronavirus EMC/2012 (HCoV-EMC) and recently renamed Middle East respiratory syndrome coronavirus (MERS-CoV), that is phylogenetically closely related to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5, which we discovered in 2007 from bats in Hong Kong, has recently emerged in the Middle East to cause a severe acute respiratory syndrome (SARS)-like infection in humans. The first laboratory-confirmed case, which in
    Document: A novel lineage C betacoronavirus, originally named human coronavirus EMC/2012 (HCoV-EMC) and recently renamed Middle East respiratory syndrome coronavirus (MERS-CoV), that is phylogenetically closely related to Tylonycteris bat coronavirus HKU4 and Pipistrellus bat coronavirus HKU5, which we discovered in 2007 from bats in Hong Kong, has recently emerged in the Middle East to cause a severe acute respiratory syndrome (SARS)-like infection in humans. The first laboratory-confirmed case, which involved a 60-year-old man from Bisha, the Kingdom of Saudi Arabia (KSA), who died of rapidly progressive community-acquired pneumonia and acute renal failure, was announced by the World Health Organization (WHO) on September 23, 2012. Since then, a total of 70 cases, including 39 fatalities, have been reported in the Middle East and Europe. Recent clusters involving epidemiologically-linked household contacts and hospital contacts in the Middle East, Europe, and Africa strongly suggested possible human-to-human transmission. Clinical and laboratory research data generated in the past few months have provided new insights into the possible animal reservoirs, transmissibility, and virulence of MERS-CoV, and the optimal laboratory diagnostic options and potential antiviral targets for MERS-CoV-associated infection.

    Search related documents:
    Co phrase search for related documents
    • active surveillance and acute cause: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active surveillance and acute phase: 1, 2
    • active surveillance and acute renal failure: 1
    • active surveillance and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active surveillance and additional cluster: 1, 2
    • active surveillance and additional testing: 1, 2, 3
    • active surveillance and local global: 1
    • active surveillance and low respiratory: 1, 2, 3, 4
    • acute cause and additional testing: 1, 2
    • acute cause and local global: 1, 2, 3
    • acute cause and low concentration: 1
    • acute cause and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute cause and low respiratory tract: 1, 2
    • acute phase and additional testing: 1
    • acute phase and liver enzyme: 1, 2
    • acute phase and low concentration: 1, 2, 3
    • acute phase and low respiratory: 1
    • acute phase and lung adenocarcinoma: 1
    • acute renal failure and low respiratory: 1